Amylin Pharmaceuticals Inc - CA San Diego, San Diego 92121

Amylin Pharmaceuticals Inc entered the industry of in 2012 and has grown to employ 1 to 4 people, generating an annual revenue of $500.000.000 to $999.999.999. The NAICS classifies this business under the code 5417112, which describes it as a . For further clarification, the SIC classifies this business under the code 2834 and described it as a . The business provides service to the BOTH market.

To acquire more information, please contact Mark Gergen, Senior Vice President by calling (858) 552-2200 during business hours. You can also write to the business’ Single Location at 9625 Towne Center Drive, San Diego, California CA 92121. You can also visit the company’s website at careers.amylin.com. View this business’ social media profiles on Twitter or on Facebbok .

Company: Amylin Pharmaceuticals Inc
Representative: Mark Gergen, Senior Vice President
Place of Business: 9625 Towne Center Drive, San Diego, CA 92121
Contact Number: (858) 552-2200
Website: careers.amylin.com
Type of Service:
SIC Number: 2834
NAICS Number: 5417112
Locality: Single Location
Market Type: B2B & B2C
Began: 2012
Income/Year: $500.000.000 to $999.999.999
Laborers: 1 to 4
Share This Company:

Amylin Pharmaceuticals Inc is a company operating from San Diego, California providing professional and relevant BOTH variables. It was founded in 2012 and registered with the SIC code 2834 as , and with the NAICS code 5417112 as .

With a current employee count of 1 to 4, Amylin Pharmaceuticals Inc has gone to report making $500.000.000 to $999.999.999 per annum on its journey towards growth. This company invites you to contact its representative Mark Gergen, Senior Vice President at (858) 552-2200 for related queries, or to locate its Single Location using the coordinates 32.8819,-117.20869.

The Single Location can also be found at the street address 9625 Towne Center Drive in San Diego, California 92121 and can be engaged online through the company website at careers.amylin.com, the company Twitter , and Facebook page .